menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Roles of Non-HDL Cholesterol in Risk Assessment and Treatment

Roles of Non-HDL Cholesterol in Risk Assessment and Treatment
RestartResume
A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinic...
  • In Partnership with

  • Overview

    A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinical dogma once focused on targeting specific lipoproteins, clinicians are now trending toward using appropriate dosages of statins for lowering non-HDL cholesterol. What are the ramifications of this change in approach, and how does the NLA weigh in on recommendations for targets and goals? To address these and other questions, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.    

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/12/19